CARA
Price
$0.42
Change
+$0.01 (+2.44%)
Updated
Dec 20 closing price
66 days until earnings call
CTXR
Price
$2.60
Change
+$0.03 (+1.17%)
Updated
Dec 20, 04:59 PM (EDT)
48 days until earnings call
Ad is loading...

CARA vs CTXR

Header iconCARA vs CTXR Comparison
Open Charts CARA vs CTXRBanner chart's image
Cara Therapeutics
Price$0.42
Change+$0.01 (+2.44%)
Volume$5.36M
CapitalizationN/A
Citius Pharmaceuticals
Price$2.60
Change+$0.03 (+1.17%)
Volume$515
CapitalizationN/A
CARA vs CTXR Comparison Chart
Loading...
CARA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CTXR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CARA vs. CTXR commentary
Dec 22, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CARA is a Hold and CTXR is a Hold.

COMPARISON
Comparison
Dec 22, 2024
Stock price -- (CARA: $0.42 vs. CTXR: $2.60)
Brand notoriety: CARA and CTXR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CARA: 298% vs. CTXR: 34%
Market capitalization -- CARA: $23.18M vs. CTXR: $20.09M
CARA [@Biotechnology] is valued at $23.18M. CTXR’s [@Biotechnology] market capitalization is $20.09M. The market cap for tickers in the [@Biotechnology] industry ranges from $464.4B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CARA’s FA Score shows that 0 FA rating(s) are green whileCTXR’s FA Score has 1 green FA rating(s).

  • CARA’s FA Score: 0 green, 5 red.
  • CTXR’s FA Score: 1 green, 4 red.
According to our system of comparison, both CARA and CTXR are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CARA’s TA Score shows that 6 TA indicator(s) are bullish while CTXR’s TA Score has 5 bullish TA indicator(s).

  • CARA’s TA Score: 6 bullish, 4 bearish.
  • CTXR’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, CARA is a better buy in the short-term than CTXR.

Price Growth

CARA (@Biotechnology) experienced а +61.30% price change this week, while CTXR (@Biotechnology) price change was -6.81% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.20%. For the same industry, the average monthly price growth was -1.27%, and the average quarterly price growth was +2.17%.

Reported Earning Dates

CARA is expected to report earnings on Feb 26, 2025.

CTXR is expected to report earnings on Feb 07, 2025.

Industries' Descriptions

@Biotechnology (-2.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CARA($23.2M) has a higher market cap than CTXR($20.1M). CARA YTD gains are higher at: -43.122 vs. CTXR (-86.252). CTXR has higher annual earnings (EBITDA): -40.86M vs. CARA (-88.8M). CARA has more cash in the bank: 42M vs. CTXR (212). CTXR has less debt than CARA: CTXR (320K) vs CARA (3.42M). CARA has higher revenues than CTXR: CARA (8.69M) vs CTXR (0).
CARACTXRCARA / CTXR
Capitalization23.2M20.1M115%
EBITDA-88.8M-40.86M217%
Gain YTD-43.122-86.25250%
P/E RatioN/AN/A-
Revenue8.69M0-
Total Cash42M21219,811,321%
Total Debt3.42M320K1,068%
FUNDAMENTALS RATINGS
CARA vs CTXR: Fundamental Ratings
CARA
CTXR
OUTLOOK RATING
1..100
9851
VALUATION
overvalued / fair valued / undervalued
1..100
86
Overvalued
8
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9997
PRICE GROWTH RATING
1..100
3798
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a95

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CTXR's Valuation (8) in the Pharmaceuticals Major industry is significantly better than the same rating for CARA (86) in the Biotechnology industry. This means that CTXR’s stock grew significantly faster than CARA’s over the last 12 months.

CTXR's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as CARA (100) in the Biotechnology industry. This means that CTXR’s stock grew similarly to CARA’s over the last 12 months.

CTXR's SMR Rating (97) in the Pharmaceuticals Major industry is in the same range as CARA (99) in the Biotechnology industry. This means that CTXR’s stock grew similarly to CARA’s over the last 12 months.

CARA's Price Growth Rating (37) in the Biotechnology industry is somewhat better than the same rating for CTXR (98) in the Pharmaceuticals Major industry. This means that CARA’s stock grew somewhat faster than CTXR’s over the last 12 months.

CARA's P/E Growth Rating (100) in the Biotechnology industry is in the same range as CTXR (100) in the Pharmaceuticals Major industry. This means that CARA’s stock grew similarly to CTXR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CARACTXR
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 6 days ago
80%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 17 days ago
85%
Declines
ODDS (%)
Bearish Trend 5 days ago
84%
Bearish Trend 3 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 4 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
78%
View a ticker or compare two or three
Ad is loading...
CARA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CTXR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DKNG40.380.98
+2.47%
DraftKings
AZUL1.790.02
+1.13%
Azul SA
SDRL36.320.14
+0.39%
Seadrill Limited
SBR62.000.12
+0.19%
Sabine Royalty Trust
BENF0.64-0.07
-10.05%
Beneficient

CTXR and

Correlation & Price change

A.I.dvisor indicates that over the last year, CTXR has been loosely correlated with EYEN. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CTXR jumps, then EYEN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CTXR
1D Price
Change %
CTXR100%
+1.17%
EYEN - CTXR
46%
Loosely correlated
-3.22%
TFFP - CTXR
37%
Loosely correlated
N/A
PSTX - CTXR
32%
Poorly correlated
+0.64%
ALEC - CTXR
31%
Poorly correlated
+4.49%
ALLO - CTXR
31%
Poorly correlated
+1.63%
More